UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the U.S. stock market opens. The company will host a live audio webcast and conference call at 10:00 AM Eastern Time, with access and a 30-day replay available via its Investor Relations website.

Market Context

URGN’s prior earnings-date announcements were followed by -3.23% and -0.71% 24-hour reactions, givin...

Analysis

URGN’s prior earnings-date announcements were followed by -3.23% and -0.71% 24-hour reactions, giving this scheduling notice a specific historical benchmark. Recent insider activity was Net Selling; investors can watch the reported results and management commentary.

Key Figures

Reporting period: Q2 2026 Results date: August 5, 2026 Conference call time: 10:00 AM Eastern Time +1 more

4 metrics

Reporting period Q2 2026 Financial results scheduled for release

Results date August 5, 2026 Prior to the stock market open

Conference call time 10:00 AM Eastern Time Live audio webcast and conference call

Replay availability Approximately 30 days Webcast replay on the Investor Relations website

Previous Earnings date Reports

2 past events · Latest: Apr 29 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Q1 earnings date	Neutral	-3.2%	Scheduled Q1 results and webcast preceded a -3.23% 24-hour reaction.
Feb 23	FY2025 earnings date	Neutral	-0.7%	Scheduled fourth-quarter and full-year results preceded a -0.71% 24-hour reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both prior earnings-date announcements were followed by negative 24-hour reactions of -3.23% and -0.71%.

Key Terms

urothelial

1 terms

urothelial medical

"developing and commercializing innovative solutions that treat urothelial and specialty cancers"

Urothelial refers to the special cells that form the lining of the urinary tract—like wallpaper lining the inside of a house—covering the bladder, ureters, renal pelvis and part of the urethra. It matters to investors because diseases of these cells, especially cancers, are a common focus for diagnostics, drugs and medical devices; regulatory approvals, trial results or new tests for urothelial conditions can materially affect company revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2026 financial results on Wednesday, August 5^th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

INVESTOR CONTACT:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

FAQ

When will UroGen Pharma (URGN) report its Q2 2026 financial results?

UroGen Pharma will report its Q2 2026 financial results on Wednesday, August 5, 2026, before the stock market opens. According to UroGen Pharma, the release will be followed by a webcast and conference call at 10:00 AM Eastern Time.

What time is UroGen Pharma's Q2 2026 earnings conference call on August 5, 2026?

UroGen Pharma's Q2 2026 earnings conference call is scheduled for 10:00 AM Eastern Time on August 5, 2026. According to UroGen Pharma, the live audio webcast will follow the financial results release before the market opens.

How can investors access UroGen Pharma (URGN) Q2 2026 earnings webcast?

Investors can access UroGen Pharma’s Q2 2026 earnings webcast via the company’s Investor Relations website. According to UroGen Pharma, a live public webcast and a replay for approximately 30 days will be available on the site.

Will there be a replay of UroGen Pharma's Q2 2026 earnings call for URGN shareholders?

Yes, a replay of UroGen Pharma's Q2 2026 earnings call will be available for about 30 days. According to UroGen Pharma, the replay can be accessed on the company’s Investor Relations website following the live webcast.

Where is UroGen Pharma headquartered and what event is it hosting on August 5, 2026?

UroGen Pharma, headquartered in Princeton, New Jersey, is hosting its Q2 2026 earnings webcast and conference call on August 5, 2026. According to UroGen Pharma, the event starts at 10:00 AM Eastern Time after results are released.